MEDISTIM ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 180 NOK | +2.86% |
|
+2.27% | -15.89% |
| 04-25 | Transcript : Medistim ASA, Q1 2024 Earnings Call, Apr 25, 2024 | |
| 04-24 | Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024 | CI |
| Sales 2024 * | 539M 48.88M 3.9B | Sales 2025 * | 563M 51.12M 4.08B | Capitalization | 3.2B 291M 23.23B |
|---|---|---|---|---|---|
| Net income 2024 * | 107M 9.71M 776M | Net income 2025 * | 118M 10.71M 855M | EV / Sales 2024 * | 5.81 x |
| Net cash position 2024 * | 78M 7.08M 565M | Net cash position 2025 * | 119M 10.8M 863M | EV / Sales 2025 * | 5.48 x |
| P/E ratio 2024 * |
29.8
x | P/E ratio 2025 * |
27.1
x | Employees | 151 |
| Yield 2024 * |
2.57% | Yield 2025 * |
1.93% | Free-Float | 74.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on Medistim ASA
More press releases
| 1 day | +2.86% | ||
| 1 week | +2.27% | ||
| Current month | -3.23% | ||
| 1 month | -6.01% | ||
| 3 months | -13.88% | ||
| 6 months | -5.26% | ||
| Current year | -15.89% |
1 week
167.00
186.50
1 month
167.00204.00
Current year
167.00232.00
1 year
167.00303.00
3 years
167.00409.00
5 years
122.00409.00
10 years
20.20409.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 31/08/09 | |
| Director of Finance/CFO | - | 31/12/00 | |
Anne Waaler
CTO | Chief Tech/Sci/R&D Officer | 68 | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 31/12/99 | |
| Director/Board Member | 54 | 31/03/23 | |
Lars Rønn
BRD | Director/Board Member | 60 | 31/12/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 180 | +2.86% | 12 921 |
| 26/04/24 | 175 | +0.57% | 2,701 |
| 25/04/24 | 174 | -6.70% | 29,751 |
| 24/04/24 | 186.5 | +5.07% | 4,654 |
| 23/04/24 | 177.5 | +0.85% | 4,082 |
Real-time Oslo Bors, April 29, 2024 at 03:25 pm
More quotes
Medistim ASA is a Norway-based company engaged in the provision of medical equipment and technology. It develops, manufactures and distributes medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the outcome of cardiac and vascular surgery. The Company provides Transit Time Flow Measurement (TTFM) and ultrasound imaging to the global market to enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. Medistimâs activities are divided into two business units: Own Products Category and Third-Party Products Category. Furthermore, the Company has several subsidiaries, including Medistim USA Inc, Medistim Norge AS and Medistim Japan KK.
Calendar
15/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
175
NOK
Average target price
190
NOK
Spread / Average Target
+8.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.89% | 290M | |
| +8.12% | 219B | |
| +6.80% | 183B | |
| +11.39% | 133B | |
| +26.05% | 108B | |
| +1.44% | 63.06B | |
| +12.22% | 52.02B | |
| -0.62% | 48.2B | |
| -0.47% | 40.37B | |
| +13.00% | 39.35B |
- Stock Market
- Equities
- MEDI Stock
